发明公开
EP2130822A1 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents
审中-公开
2,4,5- triphenylimidazolinderivate作为用作抗癌剂p53和MDM2蛋白之间相互作用的抑制剂
- 专利标题： 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents
- 专利标题（中）： 2,4,5- triphenylimidazolinderivate作为用作抗癌剂p53和MDM2蛋白之间相互作用的抑制剂
-
申请号： EP09166803.8申请日： 2006-11-22
-
公开(公告)号： EP2130822A1公开(公告)日： 2009-12-09
- 发明人: Ding, Qingjie , Graves, Bradford James , Kong, Norman , Liu, Jin-Jun , Lovey, Allen John , Pizzolato, Giacomo , Roberts, John Lawson , So, Sung-Sau , Vu, Binh Thanh , Wovkulich, Peter Michael
- 申请人： F. Hoffmann-La Roche AG
- 申请人地址： Grenzacherstrasse 124 4070 Basel CH
- 专利权人： F. Hoffmann-La Roche AG
- 当前专利权人： F. Hoffmann-La Roche AG
- 当前专利权人地址： Grenzacherstrasse 124 4070 Basel CH
- 代理机构： Halbig, Dirk
- 优先权： US741223P 20051201; US852747P 20061019
- 主分类号： C07D233/22
- IPC分类号： C07D233/22 ; C07D233/26 ; C07D401/06 ; C07D403/06 ; C07D407/12 ; C07D409/12 ; C07D471/04 ; C07D487/04 ; A61K31/4164 ; A61K31/496 ; A61P35/00
摘要：
The present invention relates to compounds of formula I
and the pharmaceutically acceptable salts and esters thereof wherein X 1 , X 2 , R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are defined as in claim. The compounds exhibit activity as anticancer agents.
and the pharmaceutically acceptable salts and esters thereof wherein X 1 , X 2 , R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are defined as in claim. The compounds exhibit activity as anticancer agents.
信息查询
